Toxicology

Hook:Two companies built nearly identical devices. One reached market in under two years with no clinical trial.The other spent three years running a costly study they […]

Short answer: combination products are often harder to develop than pure devices or pure drugs because they must satisfy multiple regulatory frameworks at the same time. Many founders assume that combining a device with a drug simply means choosing one regulatory pathway. In reality, combination products often require dual compliance, complex evidence strategies, and coordination across different parts of the U.S. Food and Drug Administration.

Short answer: the sponsor proposes a classification, but the final decision belongs to the FDA. Many companies assume they can simply decide whether their product is a device, drug, or combination product. In practice, the U.S. Food and Drug Administration determines the final regulatory classification. This matters because classification determines which regulatory center reviews the product, what evidence is required, and how long development may take.

Short answer: product misclassification rarely causes immediate failure—but it quietly destroys timelines later. Many companies begin development assuming their product is a medical device because that pathway often appears faster and less expensive. Months—or even years—later, they discover the product functions more like a drug or combination product